Meeting
2013 ASCO Annual Meeting
Evaluation of cyclophosphamide as an immune enhancer for the NY-ESO-1/ISCOMATRIX vaccine in patients with metastatic melanoma.
Authors
Oliver Klein
Ludwig Institute for Cancer Research, Melbourne, Australia
Oliver Klein , Ian D. Davis , Grant A. McArthur , Andrew Mark Haydon , Phillip Parente , Nektaria Dimopoulos , Heather Jackson , Eugene Maraskovsky , Wendie Hopkins , Rodica Stan , Weisan Chen , Jonathan S. Cebon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Vaccines
Clinical Trial Registration Number
NCT00518206
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3093^)
DOI
10.1200/jco.2013.31.15_suppl.3093
Abstract #
3093^
Poster Bd #
20D
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.
First Author: Craig L. Slingluff Jr.
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi
Poster
2023 ASCO Annual Meeting
Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.
First Author: Sofie Kirial Mørk
Poster
2020 ASCO Virtual Scientific Program
Safety and activity of autologous T cells with enhanced NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO).
First Author: Sandra P. D'Angelo